AGV Discovery outlook

Pharmaceutical research within AGV Discovery focuses on the early development of targeted therapies in oncology. Established in 2013 on the basis of the research studies of Dr. Jean-François Guichou (CBS, INSERM, Montpellier), AGV Discovery team has identified and optimized series of small molecules active on therapeutic targets involved in the process of cancer development. The vision of AGV Discovery is to bring these research projects until pharmaceutical clinical development, in the aim to provide new therapeutic options for the treatment of cancers.


Today, two research programs are underway, a selective kinase inhibitor for the treatment of melanoma and colon cancer, and several combinations of inhibitors for the treatment of more aggressive cancers such as pancreatic and lung cancer. Pharmaceutical projects are the result of a intensive scientific collaboration between AGV Discovery and academic laboratories of Montpellier (INSERM, CNRS, University of Montpellier).


  • Augmentation de capital 1er Semestre 2020

    La société AGV Discovery va procéder à une nouvelle augmentation de son capital social sur le premier semestre 2020. Pour plus d'informations, con...

  • Renouvellement d'agrément CIR2017-2019

    L'agrément "Crédit Impôt Recherche" est renouvelé pour les années 2017, 2018 et 2019....